Aliskiren how supplied storage and handling

Revision as of 15:16, 25 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Aliskiren}} {{CMG}}; {{AE}} {{SS}} ==How Supplied Storage and Handling== Tekturna is supplied as a light-pink, biconvex round tablet containing 150 mg of aliskire...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Aliskiren
TEKTURNA® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Aliskiren
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

How Supplied Storage and Handling

Tekturna is supplied as a light-pink, biconvex round tablet containing 150 mg of aliskiren, and as a light-red biconvex ovaloid tablet containing 300 mg of aliskiren. Tablets are imprinted with NVR on one side and IL, IU, on the other side of the 150, and 300 mg tablets, respectively.

All strengths are packaged in bottles and unit-dose blister packages (10 strips or 10 tablets) as described below in Table 6.

Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [See USP Controlled Room Temperature]. Protect from moisture.

Dispense in original container.[1]

References

  1. "TEKTURNA (ALISKIREN HEMIFUMARATE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]". Retrieved 25 February 2014.

Template:Agents acting on the renin-angiotensin system